BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28993503)

  • 21. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.
    Whaley-Connell A; Nistala R; Habibi J; Hayden MR; Schneider RI; Johnson MS; Tilmon R; Rehmer N; Ferrario CM; Sowers JR
    Am J Physiol Renal Physiol; 2010 Mar; 298(3):F655-61. PubMed ID: 20007350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease.
    Verver EJ; Topsakal V; Kunst HP; Huygen PL; Heller PG; Pujol-Moix N; Savoia A; Benazzo M; Fierro T; Grolman W; Gresele P; Pecci A
    Ear Hear; 2016; 37(1):112-20. PubMed ID: 26226608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypertension induces glomerulosclerosis in phospholipase C-ε1 deficiency.
    Atchison DK; O'Connor CL; Menon R; Otto EA; Ganesh SK; Wiggins RC; Smrcka AV; Bitzer M
    Am J Physiol Renal Physiol; 2020 May; 318(5):F1177-F1187. PubMed ID: 32223311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes.
    Arrondel C; Vodovar N; Knebelmann B; Grünfeld JP; Gubler MC; Antignac C; Heidet L
    J Am Soc Nephrol; 2002 Jan; 13(1):65-74. PubMed ID: 11752022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glomerular MYH9 expression is reduced by HIV-1.
    Hays T; D'Agati VD; Garellek JA; Warren T; Trubin ME; Hyink DP; He JC; Klotman PE
    AIDS; 2012 Apr; 26(7):797-803. PubMed ID: 22313957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
    Leelahavanichkul A; Yan Q; Hu X; Eisner C; Huang Y; Chen R; Mizel D; Zhou H; Wright EC; Kopp JB; Schnermann J; Yuen PS; Star RA
    Kidney Int; 2010 Dec; 78(11):1136-53. PubMed ID: 20736988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal injury associated with
    Yoshikawa K; Kunishima S; Kurihara H; Takahashi K; Fukuta A; Murai K; Echizenya T; Nakaya I; Soma J
    Clin Nephrol; 2023 Mar; 99(3):153-160. PubMed ID: 36602281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FHL2 mediates podocyte Rac1 activation and foot process effacement in hypertensive nephropathy.
    Li SY; Chu PH; Huang PH; Hsieh TH; Susztak K; Tarng DC
    Sci Rep; 2019 Apr; 9(1):6693. PubMed ID: 31040292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphorylation of ACTN4 Leads to Podocyte Vulnerability and Proteinuric Glomerulosclerosis.
    Feng D; Kumar M; Muntel J; Gurley SB; Birrane G; Stillman IE; Ding L; Wang M; Ahmed S; Schlondorff J; Alper SL; Ferrante T; Marquez SL; Ng CF; Novak R; Ingber DE; Steen H; Pollak MR
    J Am Soc Nephrol; 2020 Jul; 31(7):1479-1495. PubMed ID: 32540856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin II provokes podocyte injury in murine model of HIV-associated nephropathy.
    Ideura H; Hiromura K; Hiramatsu N; Shigehara T; Takeuchi S; Tomioka M; Sakairi T; Yamashita S; Maeshima A; Kaneko Y; Kuroiwa T; Kopp JB; Nojima Y
    Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1214-21. PubMed ID: 17652372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations.
    Pecci A; Klersy C; Gresele P; Lee KJ; De Rocco D; Bozzi V; Russo G; Heller PG; Loffredo G; Ballmaier M; Fabris F; Beggiato E; Kahr WH; Pujol-Moix N; Platokouki H; Van Geet C; Noris P; Yerram P; Hermans C; Gerber B; Economou M; De Groot M; Zieger B; De Candia E; Fraticelli V; Kersseboom R; Piccoli GB; Zimmermann S; Fierro T; Glembotsky AC; Vianello F; Zaninetti C; Nicchia E; Güthner C; Baronci C; Seri M; Knight PJ; Balduini CL; Savoia A
    Hum Mutat; 2014 Feb; 35(2):236-47. PubMed ID: 24186861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of angiotensin II signaling on cytoskeleton of podocytes.
    Hsu HH; Hoffmann S; Endlich N; Velic A; Schwab A; Weide T; Schlatter E; Pavenstädt H
    J Mol Med (Berl); 2008 Dec; 86(12):1379-94. PubMed ID: 18773185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYH9 genetic variants associated with glomerular disease: what is the role for genetic testing?
    Kopp JB; Winkler CA; Nelson GW
    Semin Nephrol; 2010 Jul; 30(4):409-17. PubMed ID: 20807613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
    Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detrimental role of sphingosine kinase 1 in kidney damage in DOCA-salt hypertensive model: evidence from knockout mice.
    Lyu B; Wang W; Ji XY; Ritter JK; Li N
    BMC Nephrol; 2020 May; 21(1):173. PubMed ID: 32393187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
    Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC
    Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of specific disease mutations in non-muscle myosin 2A on its structure and function.
    Casas-Mao D; Carrington G; Pujol MG; Peckham M
    J Biol Chem; 2024 Jan; 300(1):105514. PubMed ID: 38042490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.
    Papeta N; Kiryluk K; Patel A; Sterken R; Kacak N; Snyder HJ; Imus PH; Mhatre AN; Lawani AK; Julian BA; Wyatt RJ; Novak J; Wyatt CM; Ross MJ; Winston JA; Klotman ME; Cohen DJ; Appel GB; D'Agati VD; Klotman PE; Gharavi AG
    J Am Soc Nephrol; 2011 Nov; 22(11):1991-6. PubMed ID: 21997397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease.
    Sekine T; Konno M; Sasaki S; Moritani S; Miura T; Wong WS; Nishio H; Nishiguchi T; Ohuchi MY; Tsuchiya S; Matsuyama T; Kanegane H; Ida K; Miura K; Harita Y; Hattori M; Horita S; Igarashi T; Saito H; Kunishima S
    Kidney Int; 2010 Jul; 78(2):207-14. PubMed ID: 20200500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OPN deficiency results in severe glomerulosclerosis in uninephrectomized mice.
    Schordan S; Grisk O; Schordan E; Miehe B; Rumpel E; Endlich K; Giebel J; Endlich N
    Am J Physiol Renal Physiol; 2013 Jun; 304(12):F1458-70. PubMed ID: 23552865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.